Thursday, March 22, 2007

Soy as Prostate Cancer Protection Yields Paradoxical Results

Hi Guys,

For years I have used soy products, most particularly soy milk and tofu, but following my diagnosis of aggressive prostate cancer last May and then the public warnings of the danger associated with taking soy, I stopped taking soy milk and moved over to rice milk and oat milk. The tofu I continue to have because my research tells me that the fermentation process used, destroys the two bad elements within soy (hence, I guess, how it is that the Chinese have been consuming tofu for hundreds of years, perhaps thousands, without any perceived ill effects.)

With that background I found the following article of special interest. It appears that consuming soy in the early stages of prostate cancer may be a good thing but definitely not if it is of the aggressive type. But how would you know? Ask a specialist? Maybe! But ask two or three and you're likely to get a different answer each time. Confused? Yep, and so are they much of the time.

The answer? Take charge of your own health and wellbeing. Do your own research, talk to medical professionals; naturopaths; homeopaths, friends and neighbours. Anyone in fact who can add a smidgen of anecdotal or clinical information that will help YOU make your own, rational judgments and decisions.

I can only hope that I cut out taking soy milk in time and that I didn't, in my earlier ignorance, worsened an already worst case scenario.



Visit us online at www.MedPageToday.com


Soy as Prostate Cancer Protection Yields Paradoxical Results

By Neil Osterweil, Senior Associate Editor, MedPage Today
Reviewed by Rubeen K. Israni, M.D., Fellow, Renal-Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine
March 16, 2007


MedPage Today Action Points

Explain to patients who ask that that several studies have suggested that diets rich in soy may protect against some types of prostate cancer.


Explain that this study suggests that in addition to protection there may also be increased risk for advanced prostate cancer from high soy diets, although the reasons are unclear.

Review
TOKYO, March 16 -- Diets rich in soy protect against prostate cancer. Then again, they don't.

This paradoxical finding came from a study of 43,509 Japanese men. For some soy isoflavones in the diet decreased the risk of localized prostate cancer, but at the same time soy containing miso soup increased the risk of advanced prostate cancer.


So reported Norie Kurahashi, M.D., of the National Cancer Center of Japan, and colleagues, in the March issue of Cancer Epidemiology, Biomarkers & Prevention.


"The present findings provide no clear understanding of when or how localized cancer will develop to aggressive cancer, and of the related effect of isoflavones," said Dr. Kurahashi.


The investigators recommended that Japanese men continue their high consumption of soy from foods, but they discouraged the use of supplements.


The investigators hypothesized that soy in general, and its isoflavones genistein and daizden in particular, may attenuate but not prevent the progression of latent prostate cancer. Soy isoflavones are estrogen mimics and strong antioxidants in vitro, and appear to be protective against cancer in animal models.


The Japanese study, the largest of its kind, prospectively evaluated the relationship between soy consumption and prostate cancer in men who were part of an even larger cohort study.


The men, ages 45 to 74 years, responded to a validated questionnaire which included 147 food and beverage items, including questions about portion size and frequency of consumption.


The authors focused on the consumption of miso, a soy-based soup, and at tofu in various forms, as well as natto, or fermented soybean, and soy milk. They also looked at the consumption of the isoflavones, which they estimated based on food composition tables listing isoflavone content of Japanese foods.


The study used as its baseline the five-year follow-up interval from the Japan Public Health Center-Based Prospective Study. Beginning in 1995 and continuing through 2004, there were 307 new cases of prostate cancer: 74 advanced, 220 organ-localized, and 13 of indeterminate stage.


The authors found that intake of genistein, daidzein, miso or soy foods did not have a significant effect on the risk of developing total prostate cancer (localized and advanced) for the entire cohort.


But when they broke the data down according to cancer by stage and age they found that men older than 60 in the highest quartile of intake of three of the four items -- genistein, daidzein, and soy foods -- had significantly decreased risk for localized prostate cancer versus those in the lowest quartile.


Of the men older than 60 with localized cancer, genistein was associated with a relative risk for cancer of 0.52 (95% CI, 0.30-0.90, P for trend = 0.03) in 25,538 person-years of follow-up.


Similarly, highest consumption of daidzein was associated with a relative risk of 0.50 (95% CI, 0.28-0.88, P for trend = 0.04) in 25,276 person-years, and soy foods were associated a relative risk of 0.52 (95% CI, 0.29-0.90, P for trend = 0.01).


There were no significant differences between the highest and lowest quartiles for any of the four items among men younger than 60, however.


When the investigators looked at advanced cancer among men older than 60 in a multivariate analysis adjusted for energy intake, there was a dose-dependent increase in risk for advanced prostate cancer associated with miso soup. There was a multivariable relative risk for the highest versus lowest quartile of 2.79 (95% CI, 1.19-6.55; P for trend = 0.02). Consumption of soy foods or the isoflavones was not associated with advanced prostate cancer in multivariate analysis, however.


"In the present study, we observed a dose-dependent decrease in the risk of localized prostate cancer with isoflavone consumption," the investigators wrote. "Men with the highest intake of isoflavones (as genistein, > 32.8 mg/d) had a decreased risk of prostate cancer compared with those with the lowest intake of isoflavones (as genistein, <13.2mg/d).>

New Prostate Cancer Drug

March 22nd, 2007
Hi Guys,

This looks interesting for guys with a non-responsive, aggressive prostate cancer like mine but more so, for those following the conventional medical treatment path. Currently a no-no for me.

Tamara McLean
March 22, 2007 09:06am
Article from: The Brisbane Courier Mail

New prostate cancer drug

An experimental drug designed to fight the spread of aggressive prostate cancer is showing great promise for future sufferers, Australian developers say.

A team from the University of New South Wales is working on a new therapy for prostate cancer patients who stop responding to standard hormone treatments.
The medication is still in the development stage but if new tests prove successful, it could bring relief for a group of men for whom there is currently no treatment, said study leader Dr Kieran Scott.

“We’ve seen enough positive data to know it’s worth testing in people,” Dr Scott said.

Prostate cancer is the most common cancer in Australian men, with patients usually treated with some combination of surgery, radiation and hormone medications.

These drugs effectively limit the spread of prostate cancer in the early stages by suppressing the male hormones that tumours need to grow.

But over time cancers often stop responding to this treatment, putting men at risk of tumour growth and cancer spread to the bones.

Dr Scott said his team at St Vincent’s Hospital in Sydney believed it had a new oral medicine that could slow the growth of hormone-resistant cancer and stop its spread.

The medication works by blocking an enzyme which releases Omega-6 fatty acids - fats which, when consumed in the diet, have been associated with increased rates of disease.

“We think we can slow the growth of tumours that are resistant and we believe the drug may also help slow the growth of tumours in bones,” Dr Scott said.

“If we can help in those two areas then we’ll have a therapy for prostate cancer patients who currently have no good treatment.”

The team has been granted Cancer Council NSW funding for a new round of tests, with plans to manufacture and trial the experimental compound in the most severely-affected patients if they have success.

“I’ve been working in this area for 10 or 15 years and to be honest I didn’t think this would work,” Dr Scott said.

“But the data keeps me going because it keeps suggesting this approach really will work.”

Other cancer grants awarded include an investigation of genes that predispose people to melanoma and a study of new techniques to minimise breast cancer surgery side-effects.